Compare SUNS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | SLGL |
|---|---|---|
| Founded | 2023 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.1M | 117.8M |
| IPO Year | N/A | 2018 |
| Metric | SUNS | SLGL |
|---|---|---|
| Price | $9.23 | $68.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $13.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 138.6K | 21.8K |
| Earning Date | 03-05-2026 | 11-20-2025 |
| Dividend Yield | ★ 12.97% | N/A |
| EPS Growth | ★ 1112.46 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $19,384,703.00 | $18,970,000.00 |
| Revenue This Year | $175.51 | $122.71 |
| Revenue Next Year | $63.46 | N/A |
| P/E Ratio | $8.48 | ★ N/A |
| Revenue Growth | ★ 2540.16 | 62.04 |
| 52 Week Low | $7.80 | $4.02 |
| 52 Week High | $14.29 | $71.99 |
| Indicator | SUNS | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 81.92 |
| Support Level | $9.05 | $60.20 |
| Resistance Level | $9.39 | $71.99 |
| Average True Range (ATR) | 0.26 | 4.55 |
| MACD | -0.04 | 2.18 |
| Stochastic Oscillator | 27.92 | 85.92 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.